These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34181497)

  • 21. All-cause and disease-related health care costs associated with recurrent venous thromboembolism.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Hossou Y; Schein J; Kaatz S
    Thromb Haemost; 2013 Dec; 110(6):1288-97. PubMed ID: 24085327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
    Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
    Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.
    Khorana AA; Dalal MR; Lin J; Connolly GC
    Clinicoecon Outcomes Res; 2013; 5():101-8. PubMed ID: 23430767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
    Piver RN; Wagner VM; Levine MD; Backes FJ; Chambers LJ; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Bixel KL
    Gynecol Oncol Rep; 2023 Apr; 46():101156. PubMed ID: 36910448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
    Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations.
    Mahé I; Mayeur D; Krakowski I
    Support Care Cancer; 2016 Oct; 24(10):4105-12. PubMed ID: 27146390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
    El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
    Pelletier R
    J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
    Spyropoulos AC; Preblick R; Kwong WJ; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):532-541. PubMed ID: 27899520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
    Li S; Gao P; Qiu J; He X; Mao Y
    J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
    Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
    Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
    Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    J Med Econ; 2021; 24(1):469-478. PubMed ID: 33784916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 37. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
    Simon JA; Laliberté F; Duh MS; Pilon D; Kahler KH; Nyirady J; Davis PJ; Lefebvre P
    Menopause; 2016 Jun; 23(6):600-10. PubMed ID: 26953655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: a population-based longitudinal study.
    Cohoon KP; Leibson CL; Ransom JE; Ashrani AA; Park MS; Petterson TM; Long KH; Bailey KR; Heit JA
    Surgery; 2015 Mar; 157(3):423-31. PubMed ID: 25633736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
    Guman NAM; van Geffen RJ; Mulder FI; van Haaps TF; Hovsepjan V; Labots M; Cirkel GA; Y F L de Vos F; Ten Tije AJ; Beerepoot LV; Tjan-Heijnen VCG; van Laarhoven HWM; Hamberg P; Vulink AJE; Los M; Zwinderman AH; Ferwerda B; Lolkema MPJK; Steeghs N; Büller HR; Kamphuisen PW; van Es N
    J Thromb Haemost; 2021 Dec; 19(12):2974-2983. PubMed ID: 34409743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venous thromboembolism and effect of comorbidity in bladder cancer: A danish nationwide cohort study of 13,809 patients diagnosed between 1995 and 2011.
    Ording AG; Nielsen ME; Smith AB; Horváth-Puhó E; Sørensen HT
    Urol Oncol; 2016 Jul; 34(7):292.e1-8. PubMed ID: 26971189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.